Arrogene’s Chief Scientific Officer and co-founder, Julia Ljubimova, MD, PhD, has received a $2.8 million grant from he National Cancer Institute of the National Institutes of Health to advance her research of tumor nanoimmunology to treat cancers of the brain, breast, lung and other organs. “Our goal is to improve the body’s immune system so it [...]
Arrogene, Inc., a biotechnology company developing nano-diagnostic and therapeutic agents based on natural polymer and beta-polymalic acid, has announced that Dr. Jack Kavanaugh, a widely respected executive who has successfully led and guided multiple biotech and physical science companies, will assume the title of Chairman and Executive Chairman effective immediately. Arrogene’s technology was developed at Cedars-Sinai Medical [...]
Arrogene scientists are featured in an article about new targeted therapies to fight breast cancer. Reporter Kim Lamb Gregory interviewed Arrogene co-founder and Chief Scientific Officer: “Dr. Julia Ljubimova and her research team are testing a family of drugs for HER2- positive metastatic breast cancer called Polyolefin. The drug is nanoscale Trojan Horse that sneaks into the [...]
